Skip to content
  • About Us
  • Our Technology
  • Partnering
  • Our Team
  • News
  • Contact Us
  • About Us
  • Our Technology
  • Partnering
  • Our Team
  • News
  • Contact Us
Linkedin

Spirea completes seed funding round to develop the next generation of antibody drug conjugate therapeutics

  • July 13, 2020
  • 10:25 am
  • Spirea, a spin-out from the University of Cambridge, has developed a novel antibody drug conjugate platform and aims to reshape the future of cancer treatment.
  •  Spirea’s flexible technology achieves a high and stable drug-to-antibody ratio resulting in an improved therapeutic index to treat a wider range of patients
  • Seed investment from Meltwind and Start Codon will accelerate in vivo proof-of-concept studies which are scheduled for completion by Q4 2020

Related news

Spirea wins Innovate UK grant to advance next-generation ADC technology

Read More

Spirea announces the promotion of Dr Ludovic Juen to Principal Scientist as the company continues to advance its proprietary technology in next-generation ADCs

Read More

Spirea welcomes Dr Bo Rode Hansen as Executive Director as the company further strengthens its management and business capabilities

Read More

Contact Details

contact@spirea.co.uk 

Spirea Ltd 09817891
Windsor House
Cornwall Road
Harrogate
HG1 2PW

Linkedin
  • About Us
  • Our Technology
  • Partnering
  • Our Team
  • News
  • Contact Us
  • About Us
  • Our Technology
  • Partnering
  • Our Team
  • News
  • Contact Us